CMAB-017

N/A

Report date: 2025/12/26 16:52:14

Base Information

Drug NameCMAB-017
Drug Alias NameCMAB-017
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTaizhou Mabtech Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTaizhou Mabtech Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A